HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Clinical trials for HEPATOCELLULAR CARCINOMA NON-RESECTABLE explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULAR CARCINOMA NON-RESECTABLE trials appear
Sign up with your email to follow new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink liver tumors without surgery
Disease control Recruiting nowThis study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) to a procedure called Y-90 SIRT (tiny radioactive beads placed in the liver) can shrink intermediate-stage liver cancer that cannot be removed by surgery. About 55 adults with this type of liver…
Matched conditions: HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
One-two punch for tough liver cancer: radiation beads then immunotherapy
Disease control Recruiting nowThis study tests a two-step treatment for people with advanced liver cancer that has spread into the portal vein (a major liver blood vessel). First, tiny radioactive beads are injected into the liver to deliver targeted radiation. Then, two immunotherapy drugs are given to help …
Matched conditions: HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Phase: PHASE2 • Sponsor: Center Eugene Marquis • Aim: Disease control
Last updated May 17, 2026 01:50 UTC
-
New combo therapy aims to stop liver cancer in its tracks
Disease control Recruiting nowThis study tests whether adding targeted radiation therapy after a standard liver cancer procedure (TACE) can better control tumors in people with early or intermediate-stage liver cancer who cannot have surgery. About 30 adults aged 18-80 with 1-3 tumors (at least 4 cm total) wi…
Matched conditions: HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Phase: NA • Sponsor: RWTH Aachen University • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Proton beam plus immunotherapy shows promise against hard-to-treat liver cancer
Disease control Recruiting nowThis study tests whether adding proton radiation to standard immunotherapy (atezolizumab and bevacizumab) can improve outcomes for people with liver cancer that cannot be removed by surgery. About 45 participants will receive the combination therapy. The goal is to see if this ap…
Matched conditions: HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated May 04, 2026 16:31 UTC